Raras
Buscar doenças, sintomas, genes...
Distonia genética rara
ORPHA:391799PCDT · SUSDOENÇA RARA

Um caso de distúrbio distônico causado por uma modificação hereditária do genoma do indivíduo.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um caso de distúrbio distônico causado por uma modificação hereditária do genoma do indivíduo.

Publicações científicas
11.704 artigos
Último publicado: 2026
Medicamentos
4 registrados
ZONISAMIDE, INCOBOTULINUMTOXINA, LEVETIRACETAM

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
ZONISAMIDEINCOBOTULINUMTOXINALEVETIRACETAMABOBOTULINUMTOXINA
🏥
SUS: Cobertura mínimaScore: 30%
PCDT disponível
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
67 sintomas
💪
Músculos
33 sintomas
📏
Crescimento
25 sintomas
😀
Face
21 sintomas
🦴
Ossos e articulações
19 sintomas
👁️
Olhos
19 sintomas

+ 191 sintomas em outras categorias

Características mais comuns

Déficit de atenção
Infertilidade
Amenorreia primária
Diabetes mellitus tipo 1
Azoospermia
Mioclonia espinhal
421sintomas
Sem dados (421)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 421 características clínicas mais associadas, ordenadas por frequência.

Déficit de atençãoShort attention span
InfertilidadeInfertility
Amenorreia primáriaPrimary amenorrhea
Diabetes mellitus tipo 1Type I diabetes mellitus
Azoospermia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa2
Total histórico11.704PubMed
Últimos 10 anos200publicações
Pico2025140 papers
Linha do tempo
2024Hoje · 2026🧪 2021Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

47 genes identificados com associação a esta condição.

TMEM151ATransmembrane protein 151ADisease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

Endoplasmic reticulum membraneCell projection, axonCell projection, dendrite

MECANISMO DE DOENÇA

Episodic kinesigenic dyskinesia 3

A form of paroxysmal kinesigenic dyskinesia, a neurologic condition characterized by recurrent and brief attacks of abnormal involuntary movements. These attacks can involve dystonic postures, chorea, or athetosis. EKD3 is an autosomal dominant form with incomplete penetrance and onset in late childhood or early adolescence. Symptoms are usually triggered by sudden movement or stress, and resolve in most patients in their early twenties or later.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
180.9 TPM
Brain Frontal Cortex BA9
55.3 TPM
Córtex cerebral
55.0 TPM
Hipocampo
54.3 TPM
Substância negra
51.5 TPM
OUTRAS DOENÇAS (1)
episodic kinesigenic dyskinesia 3
HGNC:HGNC:28497UniProt:Q8N4L1
VPS16Vacuolar protein sorting-associated protein 16 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed

LOCALIZAÇÃO

Late endosome membraneLysosome membraneEarly endosomeCytoplasmic vesicle, clathrin-coated vesicleCytoplasmic vesicle, autophagosome

VIAS BIOLÓGICAS (1)
SARS-CoV-2 modulates autophagy
MECANISMO DE DOENÇA

Dystonia 30

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT30 is characterized by early onset and predominantly cervical, bulbar, orofacial, and upper limb involvement. Some patients have a more complex phenotype with neurocognitive impairment, including mild intellectual disability or psychiatric manifestations. Loss of ambulation is observed in some cases. DYT30 inheritance is autosomal dominant with incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
58.2 TPM
Cerebelo
57.8 TPM
Útero
55.9 TPM
Cérebro - Hemisfério cerebelar
54.6 TPM
Cervix Endocervix
52.0 TPM
OUTRAS DOENÇAS (1)
dystonia 30
HGNC:HGNC:14584UniProt:Q9H269
ACTBActin, cytoplasmic 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Actin is a highly conserved protein that polymerizes to produce filaments that form cross-linked networks in the cytoplasm of cells (PubMed:25255767, PubMed:29581253). Actin exists in both monomeric (G-actin) and polymeric (F-actin) forms, both forms playing key functions, such as cell motility and contraction (PubMed:29581253). In addition to their role in the cytoplasmic cytoskeleton, G- and F-actin also localize in the nucleus, and regulate gene transcription and motility and repair of damage

LOCALIZAÇÃO

Cytoplasm, cytoskeletonNucleus

VIAS BIOLÓGICAS (10)
Paradoxical activation of RAF signaling by kinase inactive BRAFSignaling by moderate kinase activity BRAF mutantsSignaling by high-kinase activity BRAF mutantsSignaling downstream of RAS mutantsMAP2K and MAPK activation
MECANISMO DE DOENÇA

Dystonia-deafness syndrome 1

An autosomal dominant form of dystonia with juvenile onset, associated with congenital or childhood-onset sensorineural deafness. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. Some DDS1 patients have dysmorphic features, skeletal anomalies, and/or mild developmental delay with impaired intellectual development.

OUTRAS DOENÇAS (7)
developmental malformations-deafness-dystonia syndromecongenital smooth muscle hamartoma, with or without hemihypertrophyBaraitser-Winter syndrome 1Becker nevus syndrome
HGNC:132UniProt:P60709
NR4A2Nuclear receptor subfamily 4 group A member 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional regulator which is important for the differentiation and maintenance of meso-diencephalic dopaminergic (mdDA) neurons during development (PubMed:15716272, PubMed:17184956). It is crucial for expression of a set of genes such as SLC6A3, SLC18A2, TH and DRD2 which are essential for development of mdDA neurons (By similarity)

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
Nuclear Receptor transcription pathwaySUMOylation of intracellular receptors
MECANISMO DE DOENÇA

Intellectual developmental disorder with language impairment and early-onset DOPA-responsive dystonia-parkinsonism

An autosomal dominant disorder characterized by global developmental delay affecting motor, cognitive, and speech domains apparent in early childhood or infancy. Most patients also show movement abnormalities, often hypotonia with later development of dopa-responsive dystonia or parkinsonism. About half of patients develop various types of seizures.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
145.8 TPM
Nervo tibial
91.0 TPM
Artéria tibial
65.0 TPM
Pituitária
49.4 TPM
Adipose Visceral Omentum
48.1 TPM
OUTRAS DOENÇAS (4)
intellectual developmental disorder with language impairment and early-onset DOPA-responsive dystonia-parkinsonismdevelopmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to a NR4A2 point mutation2q24 microdeletion syndromeautosomal dominant dopa-responsive dystonia
HGNC:7981UniProt:P43354
EIF2AK2Interferon-induced, double-stranded RNA-activated protein kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the innate immune response to viral infection (PubMed:18835251, PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral replication via the integrated stress response (ISR): EIF2S1/eIF-2-alpha phosphorylation in response to viral in

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, perinuclear region

VIAS BIOLÓGICAS (6)
ISG15 antiviral mechanismInterferon alpha/beta signalingPKR-mediated signalingInhibition of PKREvasion by RSV of host interferon responses
MECANISMO DE DOENÇA

Leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome

An autosomal dominant disorder characterized by global developmental delay apparent in early childhood, cognitive impairment, ataxia, poor or absent speech with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, and abnormal involuntary movements. Affected individuals also exhibit neurological regression in the setting of febrile illness or infection. Many patients have seizures. Brain imaging shows diffuse white matter abnormalities with poor myelination.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
62.0 TPM
Fibroblastos
24.7 TPM
Útero
21.9 TPM
Cervix Ectocervix
21.1 TPM
Cervix Endocervix
20.4 TPM
OUTRAS DOENÇAS (3)
leukoencephalopathy, developmental delay, and episodic neurologic regression syndromedystonia 33early-onset generalized limb-onset dystonia
HGNC:9437UniProt:P19525
NUP54Nucleoporin p54Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Component of the nuclear pore complex, a complex required for the trafficking across the nuclear membrane

LOCALIZAÇÃO

Nucleus, nuclear pore complexNucleus membrane

VIAS BIOLÓGICAS (10)
snRNP AssemblyHCMV Early EventsHCMV Late EventsNEP/NS2 Interacts with the Cellular Export MachineryTransport of Ribonucleoproteins into the Host Nucleus
MECANISMO DE DOENÇA

Dystonia 37, early-onset, with striatal lesions

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT37 is an autosomal recessive form characterized by the onset of progressive dystonia, dysphagia, and choreoathetosis in the first months or years of life. Affected individuals show delayed motor development and may have impaired intellectual development.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
38.1 TPM
Útero
37.6 TPM
Linfócitos
37.1 TPM
Ovário
34.9 TPM
Cervix Endocervix
34.7 TPM
OUTRAS DOENÇAS (2)
dystonia 37, early-onset, with striatal lesionsfamilial infantile bilateral striatal necrosis
HGNC:17359UniProt:Q7Z3B4
ARXHomeobox protein ARXCandidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor (PubMed:22194193, PubMed:31691806). Binds to specific sequence motif 5'-TAATTA-3' in regulatory elements of target genes, such as histone demethylase KDM5C (PubMed:22194193, PubMed:31691806). Positively modulates transcription of KDM5C (PubMed:31691806). Activates expression of KDM5C synergistically with histone lysine demethylase PHF8 and perhaps in competition with transcription regulator ZNF711; synergy may be related to enrichment of histone H3K4me3 in regulatory element

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Lissencephaly, X-linked 2

A classic type lissencephaly associated with abnormal genitalia. Patients have severe congenital or postnatal microcephaly, lissencephaly, agenesis of the corpus callosum, neonatal-onset intractable epilepsy, poor temperature regulation, chronic diarrhea, and ambiguous or underdeveloped genitalia.

OUTRAS DOENÇAS (9)
X-linked lissencephaly with abnormal genitaliaPartington syndromecorpus callosum agenesis-abnormal genitalia syndromedevelopmental and epileptic encephalopathy, 1
HGNC:18060UniProt:Q96QS3
THAP1THAP domain-containing protein 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

DNA-binding transcription regulator that regulates endothelial cell proliferation and G1/S cell-cycle progression. Specifically binds the 5'-[AT]NTNN[GT]GGCA[AGT]-3' core DNA sequence and acts by modulating expression of pRB-E2F cell-cycle target genes, including RRM1. Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1. May also have pro-apoptotic activity by potentiating both serum-withdrawal and TNF-induced apoptosis

LOCALIZAÇÃO

Nucleus, nucleoplasmNucleus, PML body

MECANISMO DE DOENÇA

Dystonia 6, torsion

A primary torsion dystonia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. Dystonia type 6 is characterized by onset in early adulthood, cranial or cervical involvement in about half of the cases, and frequent progression to involve multiple body regions.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
14.9 TPM
Fibroblastos
13.7 TPM
Linfócitos
13.5 TPM
Útero
10.9 TPM
Esôfago - Muscular
10.4 TPM
OUTRAS DOENÇAS (1)
torsion dystonia 6
HGNC:20856UniProt:Q9NVV9
TUBB4ATubulin beta-4A chainDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
HCMV Early EventsPKR-mediated signalingGap junction assemblyAggrephagyAssembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Dystonia 4, torsion, autosomal dominant

A form of torsion dystonia, a disease defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. 'Torsion' refers to the twisting nature of body movements, often affecting the trunk. DYT4 is characterized by onset in the second to third decade of progressive laryngeal dysphonia followed by the involvement of other muscles, such as the neck or limbs. Some patients develop an ataxic gait.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
988.8 TPM
Cerebelo
895.3 TPM
Brain Spinal cord cervical c-1
446.2 TPM
Brain Frontal Cortex BA9
305.6 TPM
Córtex cerebral
258.5 TPM
OUTRAS DOENÇAS (2)
torsion dystonia 4hypomyelinating leukodystrophy 6
HGNC:20774UniProt:P04350
VPS11Vacuolar protein sorting-associated protein 11 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed

LOCALIZAÇÃO

EndosomeLate endosome membraneLysosome membraneEarly endosomeCytoplasmic vesicleCytoplasmic vesicle, autophagosomeCytoplasmic vesicle, clathrin-coated vesicle

VIAS BIOLÓGICAS (1)
SARS-CoV-2 modulates autophagy
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 12

An autosomal recessive neurologic disorder characterized by developmental delay, spasticity, truncal hypotonia, acquired microcephaly, intellectual disability with variable seizure disorder, accompanied by thin corpus callosum, paucity of white matter and delayed myelination.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
60.2 TPM
Cerebelo
59.7 TPM
Cervix Endocervix
59.0 TPM
Cérebro - Hemisfério cerebelar
58.2 TPM
Ovário
55.5 TPM
OUTRAS DOENÇAS (2)
hypomyelinating leukodystrophy 12dystonia 32
HGNC:14583UniProt:Q9H270
CACNA1AVoltage-dependent P/Q-type calcium channel subunit alpha-1ACandidate gene tested inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Presynaptic depolarization and calcium channel openingRegulation of insulin secretion
MECANISMO DE DOENÇA

Spinocerebellar ataxia 6

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA), mainly caused by expansion of a CAG repeat in the coding region of CACNA1A. There seems to be a correlation between the repeat number and earlier onset of the disorder.

OUTRAS DOENÇAS (9)
migraine, familial hemiplegic, 1episodic ataxia type 2developmental and epileptic encephalopathy, 42spinocerebellar ataxia type 6
HGNC:1388UniProt:O00555
VAC14Protein VAC14 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Scaffold protein component of the PI(3,5)P2 regulatory complex which regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Pentamerizes into a star-shaped structure and nucleates the assembly of the complex. The pentamer binds a single copy each of PIKFYVE and FIG4 and coordinates both PIKfyve kinase activity and FIG4 phosphatase activity, being required to maintain normal levels of phosphatidylinositol 3-phosphate (PtdIns(3)P) and phosphatidylinosit

LOCALIZAÇÃO

Endosome membraneMicrosome membrane

VIAS BIOLÓGICAS (1)
Synthesis of PIPs at the Golgi membrane
MECANISMO DE DOENÇA

Striatonigral degeneration, childhood-onset

An autosomal recessive neurological disorder characterized by sudden childhood onset of developmental regression. Affected children develop impaired movements with dystonia, progressively become non-ambulatory and non-verbal, and exhibit striatal abnormalities on MRI.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
22.5 TPM
Baço
19.5 TPM
Fibroblastos
18.5 TPM
Útero
18.4 TPM
Pulmão
17.8 TPM
OUTRAS DOENÇAS (2)
striatonigral degeneration, childhood-onsetYunis-Varon syndrome
HGNC:25507UniProt:Q08AM6
SHQ1Protein SHQ1 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for the quantitative accumulation of H/ACA ribonucleoproteins (RNPs), including telomerase, probably through the stabilization of DKC1, from the time of its synthesis until its association with NOP10, NHP2, and NAF1 at the nascent H/ACA RNA

LOCALIZAÇÃO

Cytoplasm, cytosolNucleus, nucleoplasm

VIAS BIOLÓGICAS (1)
Telomere Extension By Telomerase
MECANISMO DE DOENÇA

Dystonia 35, childhood-onset

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT35 is an autosomal recessive form characterized by the onset of a dystonic movement disorder in the first year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
12.3 TPM
Linfócitos
10.4 TPM
Testículo
9.1 TPM
Cervix Endocervix
8.1 TPM
Tireoide
7.7 TPM
OUTRAS DOENÇAS (3)
neurodevelopmental disorder with dystonia and seizuresdystonia 35, childhood-onsetearly-onset generalized limb-onset dystonia
HGNC:25543UniProt:Q6PI26
TAF1Transcription initiation factor TFIID subunit 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 an

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (9)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
MECANISMO DE DOENÇA

Dystonia 3, torsion, X-linked

An X-linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. It has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
26.5 TPM
Cervix Endocervix
26.3 TPM
Ovário
25.0 TPM
Cervix Ectocervix
23.9 TPM
Fallopian Tube
23.4 TPM
OUTRAS DOENÇAS (2)
intellectual disability, X-linked, syndromic 33X-linked dystonia-parkinsonism
HGNC:11535UniProt:P21675
DCAF17DDB1- and CUL4-associated factor 17Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex

LOCALIZAÇÃO

MembraneNucleus, nucleolus

VIAS BIOLÓGICAS (1)
Neddylation
MECANISMO DE DOENÇA

Woodhouse-Sakati syndrome

A rare autosomal recessive disorder characterized by hypogonadism, alopecia, diabetes mellitus, intellectual disability, and extrapyramidal syndrome.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
17.9 TPM
Útero
15.5 TPM
Tireoide
14.9 TPM
Cervix Endocervix
14.2 TPM
Cervix Ectocervix
13.6 TPM
OUTRAS DOENÇAS (1)
Woodhouse-Sakati syndrome
HGNC:HGNC:25784UniProt:Q5H9S7
SPRSepiapterin reductaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the final one or two reductions in tetra-hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
MECANISMO DE DOENÇA

Dystonia, DOPA-responsive, due to sepiapterin reductase deficiency

A form of DOPA-responsive dystonia. In the majority of cases, patients manifest progressive psychomotor retardation, dystonia and spasticity. Cognitive anomalies are also often present. The disease is due to severe dopamine and serotonin deficiencies in the central nervous system caused by a defect in BH4 synthesis. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
70.4 TPM
Fígado
65.9 TPM
Cólon transverso
50.9 TPM
Estômago
50.8 TPM
Próstata
49.3 TPM
OUTRAS DOENÇAS (1)
dopa-responsive dystonia due to sepiapterin reductase deficiency
HGNC:11257UniProt:P35270
EPHB4Ephrin type-B receptor 4Candidate gene tested inRestrito
FUNÇÃO

Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 it is involved in the regulation of cell adhesion and migration, an

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
EPH-ephrin mediated repulsion of cellsEPH-Ephrin signalingEphrin signaling
MECANISMO DE DOENÇA

Lymphatic malformation 7

A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM7 is an autosomal dominant form with variable expressivity. Some individuals present with severe non-immune hydrops fetalis, which may cause perinatal demise or fully resolve after the neonatal period. Others present with no edema and have milder clinical features, such as atrial septal defect or varicose veins as adults.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
133.8 TPM
Cervix Endocervix
110.2 TPM
Baço
84.6 TPM
Ovário
83.5 TPM
Fallopian Tube
73.2 TPM
OUTRAS DOENÇAS (5)
lymphatic malformation 7capillary malformation-arteriovenous malformation 2EPHB4-related lymphatic-related hydrops fetalisvein of Galen aneurysm
HGNC:3395UniProt:P54760
CIZ1Cip1-interacting zinc finger proteinCandidate gene tested inTolerante
FUNÇÃO

May regulate the subcellular localization of CIP/WAF1

LOCALIZAÇÃO

Nucleus

OUTRAS DOENÇAS (1)
dystonia 23
HGNC:16744UniProt:Q9ULV3
GCH1GTP cyclohydrolase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Positively regulates nitric oxide synthesis in umbilical vein endothelial cells (HUVECs). May be involved in dopamine synthesis. May modify pain sensitivity and persistence. Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
MECANISMO DE DOENÇA

Hyperphenylalaninemia, BH4-deficient, B

A disease characterized by malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency, and defective neurotransmission due to depletion of the neurotransmitters dopamine and serotonin. The principal symptoms include: psychomotor retardation, tonicity disorders, convulsions, drowsiness, irritability, abnormal movements, hyperthermia, hypersalivation, and difficulty swallowing. Some patients may present a phenotype of intermediate severity between severe hyperphenylalaninemia and mild dystonia. In this intermediate phenotype, there is marked motor delay, but no intellectual disability and only minimal, if any, hyperphenylalaninemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
49.0 TPM
Linfócitos
35.0 TPM
Pulmão
24.3 TPM
Baço
16.3 TPM
Intestino delgado
15.3 TPM
OUTRAS DOENÇAS (3)
dystonia 5GTP cyclohydrolase I deficiency with hyperphenylalaninemiaautosomal dominant dopa-responsive dystonia
HGNC:4193UniProt:P30793
AOPEPAminopeptidase ODisease-causing germline mutation(s) inTolerante
FUNÇÃO

Aminopeptidase which catalyzes the hydrolysis of amino acid residues from the N-terminus of peptide or protein substrates

LOCALIZAÇÃO

Nucleus, nucleolusCytoplasm

MECANISMO DE DOENÇA

Dystonia 31

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT31 is an autosomal recessive, progressive form with onset from childhood to young adulthood. Involuntary muscle twisting movements and postural abnormalities affect the upper and lower limbs, neck, face, and trunk. Some patients may have orofacial dyskinesia resulting in articulation and swallowing difficulties.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
dystonia 31
HGNC:HGNC:1361UniProt:Q8N6M6
SGCEEpsilon-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonCell projection, dendriteGolgi apparatus

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Dystonia 11, myoclonic

A myoclonic dystonia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT11 is characterized by involuntary lightning jerks and dystonic movements and postures alleviated by alcohol. Inheritance is autosomal dominant. The age of onset, pattern of body involvement, presence of myoclonus and response to alcohol are all variable.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
121.7 TPM
Nervo tibial
89.5 TPM
Aorta
82.0 TPM
Cervix Ectocervix
78.5 TPM
Fallopian Tube
75.7 TPM
OUTRAS DOENÇAS (2)
myoclonic dystonia 11myoclonus-dystonia syndrome
HGNC:10808UniProt:O43556
ATP1A3Sodium/potassium-transporting ATPase subunit alpha-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Ion homeostasisIon transport by P-type ATPasesPotential therapeutics for SARS
MECANISMO DE DOENÇA

Dystonia 12

An autosomal dominant dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT12 patients develop dystonia and parkinsonism between 15 and 45 years of age. The disease is characterized by an unusually rapid evolution of signs and symptoms. The sudden onset of symptoms over hours to a few weeks, often associated with physical or emotional stress, suggests a trigger initiating a nervous system insult resulting in permanent neurologic disability.

OUTRAS DOENÇAS (6)
developmental and epileptic encephalopathy 99cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndromedystonia 12alternating hemiplegia of childhood 2
HGNC:801UniProt:P13637
KCNA1Potassium voltage-gated channel subfamily A member 1Candidate gene tested inTolerante
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818, PubMed:8845167). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alte

LOCALIZAÇÃO

Cell membraneMembraneCell projection, axonCytoplasmic vesiclePerikaryonEndoplasmic reticulumCell projection, dendriteCell junctionSynapsePresynaptic cell membranePresynapse

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Episodic ataxia 1

An autosomal dominant disorder characterized by brief episodes of ataxia and dysarthria. Neurological examination during and between the attacks demonstrates spontaneous, repetitive discharges in the distal musculature (myokymia) that arise from peripheral nerve. Nystagmus is absent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
56.0 TPM
Cerebelo
42.4 TPM
Brain Frontal Cortex BA9
13.3 TPM
Brain Nucleus accumbens basal ganglia
7.8 TPM
Brain Caudate basal ganglia
7.8 TPM
OUTRAS DOENÇAS (5)
episodic ataxia type 1early-infantile DEEepisodic kinesigenic dyskinesiahereditary continuous muscle fiber activity
HGNC:6218UniProt:Q09470
TOR1ATorsin-1ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates. Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specificall

LOCALIZAÇÃO

Endoplasmic reticulum lumenNucleus membraneCell projection, growth coneCytoplasmic vesicle membraneCytoplasmic vesicle, secretory vesicleCytoplasmic vesicle, secretory vesicle, synaptic vesicleCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Cargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Dystonia 1, torsion, autosomal dominant

A primary torsion dystonia, and the most common and severe form. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. Dystonia type 1 is characterized by involuntary, repetitive, sustained muscle contractions or postures involving one or more sites of the body, in the absence of other neurological symptoms. Typically, symptoms develop first in an arm or leg in middle to late childhood and progress in approximately 30% of patients to other body regions (generalized dystonia) within about five years. 'Torsion' refers to the twisting nature of body movements observed in DYT1, often affecting the trunk. Distribution and severity of symptoms vary widely between affected individuals, ranging from mild focal dystonia to severe generalized dystonia, even within families.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
47.1 TPM
Útero
27.4 TPM
Aorta
26.7 TPM
Linfócitos
26.6 TPM
Artéria tibial
25.9 TPM
OUTRAS DOENÇAS (3)
early-onset generalized limb-onset dystoniaarthrogryposis multiplex congenita 5myoclonus-dystonia syndrome
HGNC:3098UniProt:O14656
BCAP31B-cell receptor-associated protein 31Disease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Functions as a chaperone protein (PubMed:18287538, PubMed:9396746). Is one of the most abundant endoplasmic reticulum (ER) proteins (PubMed:18287538, PubMed:9396746). Plays a role in the export of secreted proteins in the ER, the recognition of abnormally folded protein and their targeting to the ER associated-degradation (ERAD) (PubMed:18287538, PubMed:9396746). Also serves as a cargo receptor for the export of transmembrane proteins (By similarity). Plays a role in the assembly of the mitochon

LOCALIZAÇÃO

Endoplasmic reticulum membraneEndoplasmic reticulum-Golgi intermediate compartment membrane

VIAS BIOLÓGICAS (1)
Antigen Presentation: Folding, assembly and peptide loading of class I MHC
MECANISMO DE DOENÇA

Deafness, dystonia, and cerebral hypomyelination

An X-linked recessive syndrome characterized by sensorineural deafness, intellectual disability, dysmorphic facial features, dystonia, pyramidal signs, almost no psychomotor development, and hypomyelination on brain imaging.

OUTRAS DOENÇAS (2)
severe motor and intellectual disabilities-sensorineural deafness-dystonia syndromeCADDS
HGNC:16695UniProt:P51572
COL6A3Collagen alpha-3(VI) chainDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Bethlem myopathy 1C

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. BTHLM1C inheritance is autosomal dominant.

OUTRAS DOENÇAS (6)
dystonia 27Ullrich congenital muscular dystrophy 1CBethlem myopathy 1Cintermediate collagen VI-related muscular dystrophy
HGNC:2213UniProt:P12111
PDE10AcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10ADisease-causing germline mutation(s) inRestrito
FUNÇÃO

Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides (PubMed:10373451, PubMed:10393245, PubMed:16330539, PubMed:17389385, PubMed:27058447). Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate (PubMed:10373451, PubMed:10393245, PubMed:17389385, PubMed:27058447). May play a critical role in regulating cAMP and cGMP levels in the striatum, a region of the brain that contributes to the cont

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (2)
G alpha (s) signalling eventscGMP effects
MECANISMO DE DOENÇA

Dyskinesia, limb and orofacial, infantile-onset

An autosomal recessive, early-onset hyperkinetic movement disorder characterized by axial hypotonia, dyskinesia of the limbs and trunk, orofacial dyskinesia, drooling, and dysarthria. The severity of the hyperkinesis is variable.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Caudate basal ganglia
11.8 TPM
Brain Putamen basal ganglia
11.0 TPM
Brain Nucleus accumbens basal ganglia
7.5 TPM
Cérebro - Hemisfério cerebelar
6.5 TPM
Cerebelo
5.9 TPM
OUTRAS DOENÇAS (3)
striatal degeneration, autosomal dominant 2infantile-onset generalized dyskinesia with orofacial involvementchildhood-onset benign chorea with striatal involvement
HGNC:8772UniProt:Q9Y233
DRD2D(2) dopamine receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
Dopamine receptors
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
81.4 TPM
Brain Nucleus accumbens basal ganglia
51.9 TPM
Brain Putamen basal ganglia
45.7 TPM
Brain Caudate basal ganglia
40.7 TPM
Glândula salivar
11.4 TPM
OUTRAS DOENÇAS (1)
myoclonus-dystonia syndrome
HGNC:3023UniProt:P14416
ATMSerine-protein kinase ATMCandidate gene tested inTolerante
FUNÇÃO

Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). Recognizes the substrate c

LOCALIZAÇÃO

NucleusCytoplasmic vesicleCytoplasm, cytoskeleton, microtubule organizing center, centrosomePeroxisome matrix

VIAS BIOLÓGICAS (5)
DNA Damage/Telomere Stress Induced SenescenceSensing of DNA Double Strand BreaksTP53 Regulates Transcription of DNA Repair GenesMeiotic recombinationRegulation of HSF1-mediated heat shock response
MECANISMO DE DOENÇA

Ataxia telangiectasia

A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.

OUTRAS DOENÇAS (9)
ataxia telangiectasiaATM-related cancer predispositionfamilial colorectal cancer type XB-cell chronic lymphocytic leukemia
HGNC:795UniProt:Q13315
KMT2BHistone-lysine N-methyltransferase 2BDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:17707229, PubMed:25561738). Likely plays a redundant role with KMT2C in enriching H3K4me1 marks on primed and active enhancer elements (PubM

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Formation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Dystonia 28, childhood-onset

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT28 is an autosomal dominant, progressive form characterized by onset in the first decade of life and variable severity. Dystonia begins focally in the lower limbs, resulting in gait difficulties, with later progression to other body regions, including the upper limbs, neck, and orofacial region.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
77.1 TPM
Tireoide
51.5 TPM
Cerebelo
49.0 TPM
Ovário
48.3 TPM
Cervix Endocervix
46.0 TPM
OUTRAS DOENÇAS (3)
intellectual developmental disorder, autosomal dominant 68dystonia 28, childhood-onsetcomplex neurodevelopmental disorder
HGNC:15840UniProt:Q9UMN6
PNKPBifunctional polynucleotide phosphatase/kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways (PubMed:10446192, PubMed:10446193, PubMed:15385968, PubMed:20852255, PubMed:28453785). Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone (PubMed:10446192, PubMed:10446

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (1)
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
MECANISMO DE DOENÇA

Microcephaly, seizures, and developmental delay

An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
66.8 TPM
Tireoide
63.9 TPM
Baço
59.2 TPM
Glândula adrenal
55.9 TPM
Cervix Endocervix
51.8 TPM
OUTRAS DOENÇAS (4)
microcephaly, seizures, and developmental delayataxia - oculomotor apraxia type 4Charcot-Marie-Tooth disease type 2B2early-infantile DEE
HGNC:9154UniProt:Q96T60
KCNN2Small conductance calcium-activated potassium channel protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Small conductance calcium-activated potassium channel that mediates the voltage-independent transmembrane transfer of potassium across the cell membrane through a constitutive interaction with calmodulin which binds the intracellular calcium allowing its opening (PubMed:10991935, PubMed:33242881, PubMed:9287325). The current is characterized by a voltage-independent activation, an intracellular calcium concentration increase-dependent activation and a single-channel conductance of about 3 picosi

LOCALIZAÇÃO

MembraneCytoplasm, myofibril, sarcomere, Z line

VIAS BIOLÓGICAS (2)
Ca2+ activated K+ channelsAcetylcholine inhibits contraction of outer hair cells
MECANISMO DE DOENÇA

Dystonia 34, myoclonic

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT34 is an autosomal dominant form characterized by childhood-onset dystonia predominantly affecting hands and neck, with a fast tremor with superimposed myoclonus and, in some individuals, subtle cerebellar signs.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula adrenal
24.6 TPM
Pituitária
9.5 TPM
Cerebelo
9.4 TPM
Cérebro - Hemisfério cerebelar
7.6 TPM
Córtex cerebral
5.4 TPM
OUTRAS DOENÇAS (2)
neurodevelopmental disorder with or without variable movement or behavioral abnormalitiesdystonia 34, myoclonic
HGNC:HGNC:6291UniProt:Q9H2S1
KCTD17BTB/POZ domain-containing protein KCTD17Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate-adapter for CUL3-RING ubiquitin ligase complexes which mediates the ubiquitination and subsequent proteasomal degradation of TCHP, a protein involved in ciliogenesis down-regulation. Thereby, positively regulates ciliogenesis, playing a crucial role in the initial steps of axoneme extension (PubMed:25270598). May also play a role in endoplasmic reticulum calcium ion homeostasis (PubMed:25983243)

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Dystonia 26, myoclonic

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT26 is an autosomal dominant, progressive disorder characterized by a combination of non-epileptic myoclonic jerks and dystonia. Affected individuals manifest myoclonic jerks in the upper limbs during the first or second decade of life, and later develop dystonia with predominant involvement of the craniocervical regions and sometimes the trunk and/or lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Caudate basal ganglia
112.4 TPM
Brain Putamen basal ganglia
103.4 TPM
Testículo
86.7 TPM
Brain Nucleus accumbens basal ganglia
78.9 TPM
Brain Frontal Cortex BA9
67.5 TPM
OUTRAS DOENÇAS (2)
myoclonic dystonia 26myoclonus-dystonia syndrome
HGNC:25705UniProt:Q8N5Z5
SLC18A2Synaptic vesicular amine transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. Transports a variety of catecholamines such as dopamine, adrenaline and noradrenaline, histamine, and indolamines such as serotonin (PubMed:23363473, PubMed:

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle membraneCell projection, axonCell projection, dendrite

VIAS BIOLÓGICAS (3)
Serotonin Neurotransmitter Release CycleDopamine Neurotransmitter Release CycleNorepinephrine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Parkinsonism-dystonia 2, infantile-onset

An autosomal recessive disorder characterized by infantile onset of abnormal movements, including parkinsonism, dystonia, and poor fine motor skills, as well as autonomic dysfunction, including abnormal sweating, cold extremities, and poor sleep. Some patients have variable degrees of developmental delay.

EXPRESSÃO TECIDUAL(Tecido-específico)
Vagina
8.0 TPM
Ovário
6.9 TPM
Cervix Endocervix
6.0 TPM
Cervix Ectocervix
5.9 TPM
Pulmão
5.4 TPM
OUTRAS DOENÇAS (1)
brain dopamine-serotonin vesicular transport disease
HGNC:10935UniProt:Q05940
PRKRAInterferon-inducible double-stranded RNA-dependent protein kinase activator ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Activates EIF2AK2/PKR in the absence of double-stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53 association and sumoylation and phosphorylation of p53/TP53 at 'Lys-386' at 'Ser-392' respectively and enhances it

LOCALIZAÇÃO

Cytoplasm, perinuclear regionCytoplasm

VIAS BIOLÓGICAS (2)
MicroRNA (miRNA) biogenesisSmall interfering RNA (siRNA) biogenesis
MECANISMO DE DOENÇA

Dystonia 16

An early-onset dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT16 patients have progressive, generalized dystonia with axial muscle involvement, oro-mandibular (sardonic smile) and laryngeal dystonia and, in some cases, parkinsonian features.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
67.7 TPM
Aorta
59.4 TPM
Músculo esquelético
54.4 TPM
Útero
52.1 TPM
Artéria coronária
50.8 TPM
OUTRAS DOENÇAS (1)
dystonia 16
HGNC:9438UniProt:O75569
HPCANeuron-specific calcium-binding protein hippocalcinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Calcium-binding protein that may play a role in the regulation of voltage-dependent calcium channels (PubMed:28398555). May also play a role in cyclic-nucleotide-mediated signaling through the regulation of adenylate and guanylate cyclases (By similarity)

LOCALIZAÇÃO

Cytoplasm, cytosolMembrane

MECANISMO DE DOENÇA

Dystonia 2, torsion, autosomal recessive

A form of torsion dystonia, a disease defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. 'Torsion' refers to the twisting nature of body movements, often affecting the trunk. DYT2 is a slowly progressive form that first affects distal limbs and later involves the neck, orofacial, and craniocervical regions.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Caudate basal ganglia
825.3 TPM
Brain Putamen basal ganglia
677.5 TPM
Brain Nucleus accumbens basal ganglia
553.9 TPM
Hipocampo
211.7 TPM
Brain Frontal Cortex BA9
179.8 TPM
OUTRAS DOENÇAS (1)
torsion dystonia 2
HGNC:5144UniProt:P84074
GNALGuanine nucleotide-binding protein G(olf) subunit alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Guanine nucleotide-binding protein (G protein) involved as transducer in olfactory signal transduction controlled by G protein-coupled receptors (GPCRs) (By similarity). Contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Adenylate cyclase inhibitory pathwayAdenylate cyclase activating pathwayOlfactory Signaling Pathway
MECANISMO DE DOENÇA

Dystonia 25

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT25 is an autosomal dominant neurologic disorder characterized by adult onset of focal dystonia, usually involving the neck. The dystonia most often progresses to involve other regions, particularly the face and laryngeal muscles, and less commonly the trunk and limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Nucleus accumbens basal ganglia
45.6 TPM
Brain Caudate basal ganglia
28.9 TPM
Brain Putamen basal ganglia
21.6 TPM
Pituitária
18.9 TPM
Bladder
12.9 TPM
OUTRAS DOENÇAS (1)
dystonia 25
HGNC:4388UniProt:P38405
MECREnoyl-[acyl-carrier-protein] reductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:12654921, PubMed:18479707, PubMed:27817865). May provide the octanoyl chain used for lipoic acid bio

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
MECANISMO DE DOENÇA

Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities

An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
16.3 TPM
Nervo tibial
15.9 TPM
Útero
15.8 TPM
Cervix Endocervix
15.2 TPM
Cervix Ectocervix
14.8 TPM
OUTRAS DOENÇAS (3)
dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalitiesoptic atrophy 16obsolete autosomal recessive optic atrophy
HGNC:19691UniProt:Q9BV79
WARS2Tryptophan--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of tryptophan to tRNA(Trp) in a two-step reaction: tryptophan is first activated by ATP to form Trp-AMP and then transferred to the acceptor end of tRNA(Trp)

LOCALIZAÇÃO

Mitochondrion matrixMitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures

An autosomal recessive, mitochondrial disorder with a broad phenotypic spectrum ranging from severe neonatal lactic acidosis, encephalomyopathy and early death to an attenuated course with milder manifestations. Clinical features include delayed psychomotor development, intellectual disability, hypotonia, dystonia, ataxia, and spasticity. Severe combined respiratory chain deficiency may be found in severely affected individuals.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
14.8 TPM
Linfócitos
13.3 TPM
Cervix Endocervix
12.3 TPM
Ovário
11.9 TPM
Nervo tibial
11.9 TPM
OUTRAS DOENÇAS (3)
neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizuresparkinsonism-dystonia 3, childhood-onsetparkinsonism-dystonia, infantile
HGNC:12730UniProt:Q9UGM6
PRRT2Proline-rich transmembrane protein 2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

As a component of the outer core of AMPAR complex, may be involved in synaptic transmission in the central nervous system. In hippocampal neurons, in presynaptic terminals, plays an important role in the final steps of neurotransmitter release, possibly by regulating Ca(2+)-sensing. In the cerebellum, may inhibit SNARE complex formation and down-regulate short-term facilitation

LOCALIZAÇÃO

Cell membranePresynaptic cell membraneSynapseCell projection, axonCytoplasmic vesicle, secretory vesicle, synaptic vesicle membranePostsynaptic density membraneCell projection, dendritic spine

MECANISMO DE DOENÇA

Episodic kinesigenic dyskinesia 1

An autosomal dominant form of paroxysmal kinesigenic dyskinesia, a neurologic condition characterized by recurrent and brief attacks of abnormal involuntary movements, triggered by sudden voluntary movement. These attacks usually have onset during childhood or early adulthood and can involve dystonic postures, chorea, or athetosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
606.4 TPM
Cérebro - Hemisfério cerebelar
563.4 TPM
Ovário
183.2 TPM
Brain Frontal Cortex BA9
167.2 TPM
Córtex cerebral
152.5 TPM
OUTRAS DOENÇAS (9)
episodic kinesigenic dyskinesia 1seizures, benign familial infantile, 2infantile convulsions and choreoathetosisfamilial or sporadic hemiplegic migraine
HGNC:30500UniProt:Q7Z6L0
SLC6A3Sodium-dependent dopamine transporterDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)

LOCALIZAÇÃO

Cell membraneCell projection, neuron projectionCell projection, axon

VIAS BIOLÓGICAS (2)
Dopamine clearance from the synaptic cleftSLC-mediated transport of neurotransmitters
MECANISMO DE DOENÇA

Parkinsonism-dystonia 1, infantile-onset

An autosomal recessive neurodegenerative disorder characterized by infantile onset of parkinsonism and dystonia. Other neurologic features include global developmental delay, bradykinesia and pyramidal tract signs.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
34.7 TPM
Tireoide
1.8 TPM
Ovário
1.1 TPM
Cervix Ectocervix
1.1 TPM
Testículo
0.9 TPM
OUTRAS DOENÇAS (3)
classic dopamine transporter deficiency syndromeparkinsonism-dystonia, infantiletobacco addiction, susceptibility to
HGNC:11049UniProt:Q01959
ANO3Anoctamin-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylcholine and galactosylceramide (By similarity). Seems to act as potassium channel regulator and may inhibit pain signaling; can facilitate KCNT1/Slack channel activity by promoting its full single-channel conductance at very low sodium concentrations and by increasing its sodium sensitivity (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity (PubMed:21984732)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Induction of Cell-Cell FusionStimuli-sensing channels
MECANISMO DE DOENÇA

Dystonia 24

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT24 is an autosomal dominant focal dystonia affecting the neck, laryngeal muscles, and muscles of the upper limbs.

INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
dystonia 24
HGNC:14004UniProt:Q9BYT9
KCNJ10ATP-sensitive inward rectifier potassium channel 10Candidate gene tested inModerado
FUNÇÃO

May be responsible for potassium buffering action of glial cells in the brain (By similarity). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it (PubMed:8995301). Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages (PubMed:8995301). The inward rectification is mainly d

LOCALIZAÇÃO

MembraneBasolateral cell membrane

VIAS BIOLÓGICAS (3)
Activation of G protein gated Potassium channelsInhibition of voltage gated Ca2+ channels via Gbeta/gamma subunitsPotassium transport channels
MECANISMO DE DOENÇA

Seizures, sensorineural deafness, ataxia, impaired intellectual development, and electrolyte imbalance

A complex disorder characterized by generalized seizures with onset in infancy, delayed psychomotor development, ataxia, sensorineural hearing loss, hypokalemia, metabolic alkalosis, and hypomagnesemia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
132.0 TPM
Brain Caudate basal ganglia
61.6 TPM
Substância negra
60.1 TPM
Brain Putamen basal ganglia
56.0 TPM
Córtex cerebral
49.6 TPM
OUTRAS DOENÇAS (4)
autosomal recessive nonsyndromic hearing loss 4EAST syndromePendred syndromeepisodic kinesigenic dyskinesia
HGNC:6256UniProt:P78508
SLC2A1Solute carrier family 2, facilitated glucose transporter member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative trans

LOCALIZAÇÃO

Cell membraneMelanosomePhotoreceptor inner segment

VIAS BIOLÓGICAS (3)
Vitamin C (ascorbate) metabolismCellular hexose transportRegulation of insulin secretion
MECANISMO DE DOENÇA

GLUT1 deficiency syndrome 1

A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
703.8 TPM
Skin Not Sun Exposed Suprapubic
272.6 TPM
Skin Sun Exposed Lower leg
265.8 TPM
Vagina
176.1 TPM
Esôfago - Mucosa
154.8 TPM
OUTRAS DOENÇAS (8)
childhood onset GLUT1 deficiency syndrome 2hereditary cryohydrocytosis with reduced stomatindystonia 9encephalopathy due to GLUT1 deficiency
HGNC:11005UniProt:P11166
PNKDProbable thioesterase PNKDDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable thioesterase that may play a role in cellular detoxification processes; it likely acts on a yet-unknown alpha-hydroxythioester substrate (Probable). In vitro, it is able to catalyze the hydrolysis of S-D-lactoyl-glutathione to form glutathione and D-lactic acid at very low rate, though this reaction is not physiologically relevant in vivo (PubMed:21487022)

LOCALIZAÇÃO

Cell membraneMitochondrionCytoplasmGolgi apparatusEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Paroxysmal non-kinesigenic dyskinesia 1

An autosomal dominant movement disorder characterized by attacks of dystonia, chorea, and athetosis. The attacks of involuntary movements are brought on by stress, alcohol, fatigue or caffeine, and generally last between a few seconds and four hours or longer. The attacks may begin in one limb and spread throughout the body, including the face.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
73.9 TPM
Brain Frontal Cortex BA9
70.5 TPM
Próstata
54.4 TPM
Tireoide
54.3 TPM
Córtex cerebral
52.6 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
paroxysmal nonkinesigenic dyskinesia 1paroxysmal nonkinesigenic dyskinesia
HGNC:9153UniProt:Q8N490
TSPOAP1Peripheral-type benzodiazepine receptor-associated protein 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Required for synaptic transmission regulation (PubMed:33539324). It probably controls the recruitment of voltage-gated calcium channels to the presynaptic membrane, and modulates neurotransmitter release

LOCALIZAÇÃO

CytoplasmMitochondrion

VIAS BIOLÓGICAS (6)
Serotonin Neurotransmitter Release CycleGlutamate Neurotransmitter Release CycleNorepinephrine Neurotransmitter Release CycleAcetylcholine Neurotransmitter Release CycleDopamine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Dystonia 22, adult-onset

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT22AO is an autosomal recessive form characterized by focal dystonia or tremor and mild cognitive impairment.

EXPRESSÃO TECIDUAL(Ubíquo)
Córtex cerebral
88.0 TPM
Brain Anterior cingulate cortex BA24
77.8 TPM
Cerebelo
74.0 TPM
Brain Frontal Cortex BA9
72.3 TPM
Cérebro - Amígdala
59.8 TPM
OUTRAS DOENÇAS (3)
dystonia 22, juvenile-onsetdystonia 22, adult-onsetTH-deficient dopa-responsive dystonia
HGNC:16831UniProt:O95153
IMPDH2Inosine-5'-monophosphate dehydrogenase 2Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth (PubMed:7763314, PubMed:7903306). Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism (PubMed:14766016). It may also have a role in the development of malignancy and the growth progress

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (3)
Purine ribonucleoside monophosphate biosynthesisAzathioprine ADMEPotential therapeutics for SARS
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
678.8 TPM
Fibroblastos
469.7 TPM
Cervix Endocervix
400.2 TPM
Linfócitos
387.6 TPM
Cervix Ectocervix
363.9 TPM
OUTRAS DOENÇAS (1)
autosomal dominant dopa-responsive dystonia
HGNC:6053UniProt:P12268

Medicamentos e terapias

ZONISAMIDEPhase 3

Mecanismo: Sodium channel alpha subunit blocker

INCOBOTULINUMTOXINAPhase 3

Mecanismo: Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor

LEVETIRACETAMPhase 2

Mecanismo: Voltage-gated N-type calcium channel alpha-1B subunit blocker

ABOBOTULINUMTOXINAPhase 1

Mecanismo: Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

353 variantes patogênicas registradas no ClinVar.

🧬 TMEM151A: NM_153266.4(TMEM151A):c.877G>T (p.Ala293Ser) ()
🧬 TMEM151A: NM_153266.4(TMEM151A):c.391G>T (p.Asp131Tyr) ()
🧬 TMEM151A: NM_153266.4(TMEM151A):c.827C>T (p.Pro276Leu) ()
🧬 TMEM151A: NM_153266.4(TMEM151A):c.305del (p.Pro102fs) ()
🧬 TMEM151A: GRCh37/hg19 11q12.1-13.3(chr11:56895955-69295402)x3 ()
Ver todas no ClinVar

Vias biológicas (Reactome)

200 vias biológicas associadas aos genes desta condição.

SARS-CoV-2 modulates autophagy Translocation of SLC2A4 (GLUT4) to the plasma membrane Gap junction degradation Formation of annular gap junctions Regulation of actin dynamics for phagocytic cup formation HATs acetylate histones Prefoldin mediated transfer of substrate to CCT/TriC Folding of actin by CCT/TriC EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells Adherens junctions interactions Recycling pathway of L1 VEGFA-VEGFR2 Pathway Interaction between L1 and Ankyrins Cell-extracellular matrix interactions B-WICH complex positively regulates rRNA expression RHO GTPases activate IQGAPs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins MAP2K and MAPK activation UCH proteinases DNA Damage Recognition in GG-NER Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Clathrin-mediated endocytosis RHOF GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Sensory processing of sound by inner hair cells of the cochlea Nuclear Receptor transcription pathway SUMOylation of intracellular receptors ISG15 antiviral mechanism Inhibition of PKR SUMOylation of immune response proteins Interferon alpha/beta signaling Evasion by RSV of host interferon responses PKR-mediated signaling Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs snRNP Assembly SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events Postmitotic nuclear pore complex (NPC) reformation SARS-CoV-2 activates/modulates innate and adaptive immune responses SLIT2 gene expression is stimulated by ISL1 Primary multipotent pancreatic progenitor cell produces trunk bipotent pancreatic progenitor cell Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane Gap junction assembly MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Formation of tubulin folding intermediates by CCT/TriC Post-chaperonin tubulin folding pathway Hedgehog 'off' state Anchoring of the basal body to the plasma membrane Cargo trafficking to the periciliary membrane Intraflagellar transport COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Carboxyterminal post-translational modifications of tubulin Presynaptic depolarization and calcium channel opening Regulation of insulin secretion Synthesis of PIPs at the Golgi membrane Synthesis of PIPs at the early endosome membrane Synthesis of PIPs at the late endosome membrane Telomere Extension By Telomerase HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome RNA Polymerase II Pre-transcription Events Regulation of TP53 Activity through Phosphorylation RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance Neddylation Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation eNOS activation EPH-Ephrin signaling Ephrin signaling AOPEP:Zn2+ hydrolyses AGT(35-41) to AGT(36-41) RETRACTED: AOPEP:Zn2+ hydrolyses AGT(35-41) to AGT(36-41) Formation of the dystrophin-glycoprotein complex (DGC) Ion homeostasis Ion transport by P-type ATPases Potential therapeutics for SARS Voltage gated Potassium channels Cargo recognition for clathrin-mediated endocytosis Apoptotic cleavage of cellular proteins Apoptotic execution phase RHOA GTPase cycle Antigen Presentation: Folding, assembly and peptide loading of class I MHC RSV-host interactions Collagen degradation Collagen biosynthesis and modifying enzymes Signaling by PDGF Assembly of collagen fibrils and other multimeric structures Integrin cell surface interactions ECM proteoglycans NCAM1 interactions Collagen chain trimerization cGMP effects G alpha (s) signalling events Dopamine receptors DNA Damage/Telomere Stress Induced Senescence Autodegradation of the E3 ubiquitin ligase COP1 HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 Regulates Transcription of Caspase Activators and Caspases Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation G2/M DNA damage checkpoint Stabilization of p53 Meiotic recombination Pexophagy Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2 Formation of the beta-catenin:TCF transactivating complex PKMTs methylate histone lysines Deactivation of the beta-catenin transactivating complex RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function Formation of WDR5-containing histone-modifying complexes APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway Ca2+ activated K+ channels Acetylcholine inhibits contraction of outer hair cells Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle MicroRNA (miRNA) biogenesis Small interfering RNA (siRNA) biogenesis Adenylate cyclase activating pathway Adenylate cyclase inhibitory pathway Olfactory Signaling Pathway Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Mitochondrial tRNA aminoacylation Dopamine clearance from the synaptic cleft SLC-mediated transport of neurotransmitters Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) Stimuli-sensing channels Induction of Cell-Cell Fusion Activation of G protein gated Potassium channels Potassium transport channels Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits Cellular hexose transport Vitamin C (ascorbate) metabolism Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) Lactose synthesis Complex IV assembly Pregnenolone biosynthesis Glutamate Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Neutrophil degranulation Purine ribonucleoside monophosphate biosynthesis Azathioprine ADME

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 21
1Fase 11
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distonia genética rara

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity.

Journal of inherited metabolic disease2026 Mar

Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder caused by biallelic pathogenic variants in the Th gene, leading to a deficiency in the rate-limiting enzyme for the synthesis of dopamine (DA) and other catecholamine neurotransmitters. THD is associated with dystonia and infantile parkinsonism with a broad and complex spectrum and variable response to l-Dopa therapy. TH1-p.R202H is a frequent THD variant that affects TH stability and activity. The Th knock-in (Th-ki) mice with the equivalent mutation (Th-p.R203H) present reduced TH and DA levels, biological and molecular alterations, different phosphorylation patterns and altered distribution of dopaminergic markers relative to wild-type mice. Th-ki mice displayed significantly reduced TH, especially in the striatum, but also in the cortex, olfactory bulb, cerebellum, substantia nigra, globus pallidus, and spinal cord, a decrease that is not associated with dopaminergic neuronal degeneration. No changes were observed in Th-mRNA expression, and the decreased level of TH in the concrete brain areas in Th-ki mice appears to be due to defective TH protein axonal transport. Moreover, we characterized the development of dopaminergic neurons in the substantia nigra and neuronal plasticity in various brain regions. Our results indicated that alterations in TH expression within specific striatal GABAergic interneurons due to TH deficiency may potentially disrupt the balance of inhibitory neurotransmission in the striatum. Overall, our findings demonstrate that TH deficiency disrupts striatal inhibitory circuitry and triggers compensatory neuronal plasticity, without causing neuronal degeneration.

#2

Expanding the Phenotypic Spectrum of the Recurrent De Novo FBXO31 p.Asp334Asn Variant: Evidence for a Novel Neurodevelopmental Disorder (Kruer Syndrome).

Clinical genetics2026 Mar 20

Biallelic loss-of-function variants in FBXO31 cause autosomal-recessive intellectual disability. A recurrent de novo variant, c.1000G>A(p.Asp334Asn), has been described in association with an autosomal-dominant phenotype. To refine this phenotype and its clinical implications, we re-evaluated three published cases and ascertained four additional probands via advocacy networks, GeneMatcher, and clinician referral. Phenotyping included neurologic, behavioral, and dysmorphology assessment. All seven individuals carried the recurrent de novo FBXO31 p.Asp334Asn variant. A core neurodevelopmental profile was observed and included cerebral palsy (mixed hypotonia, spasticity, and dystonia), global developmental delay/intellectual disability, and speech impairment. Neuropsychiatric features were sometimes prominent and included attention-deficit/hyperactivity disorder, anxiety, stereotypies, autistic features, and behavioral dysregulation. Neuroimaging often showed a hypoplastic corpus callosum and posterior-predominant white-matter changes. In one individual, gray matter heterotopias were also observed. A subtle but consistent facial gestalt was noted. Recurrent FBXO31 p.Asp334Asn variants lead to a recognizable neurodevelopmental syndrome. Based on our findings, we recommend including FBXO31 in diagnostic algorithms for cerebral palsy and neurodevelopmental disorders. We propose the descriptive term "autosomal dominant FBXO31-associated neurodevelopmental disorder," and-consistent with the validating laboratory and with support from the FBXO31 Foundation-propose the eponym "Kruer syndrome."

#3

Expanding the Genotypic Spectrum of SLC18A2 Mutation-Related Disorder-A Novel Mutation and Review of Literature.

Journal of child neurology2026 Mar 10

Brain monoamine vesicular transporter deficiency is a rare autosomal recessive neurometabolic disorder caused by mutations in the SLC18A2 gene, which encodes vesicular monoamine transporter 2 (VMAT2). VMAT2 is essential for packaging neurotransmitters such as dopamine, serotonin, norepinephrine, and histamine into synaptic vesicles. Its deficiency results in disrupted neurotransmission and a characteristic clinical syndrome involving developmental delay, hypotonia, movement disorders, and autonomic dysfunction. We report a novel homozygous frameshift variant, Chr10:119014792dupC (p.Phe238LeufsTer7), identified in a 5-month-old male from a consanguineous family, who presented with severe hypotonia, oculogyric crises, and developmental delay. This variant expands the known genotypic spectrum of SLC18A2-related disease. Our findings underscore the importance of early genetic testing in infants with unexplained movement disorders and support a multidisciplinary approach to care. We also compare this case to related neurometabolic disorders with overlapping clinical features and with prior SLC18A2 mutation-related disorder.

#4

Neuroradiological Phenotype Expansion of the Siddiqi Syndrome: A Case Report.

Cellular and molecular neurobiology2026 Feb 27

Siddiqi syndrome is a rare autosomal recessive deafness-dystonia disorder caused by pathogenic variants in the FITM2 gene. To date, only 5 unrelated families have been reported in the literature carrying loss-of-function variants in FIMT2 gene. In this report, we describe a 29-year-old woman with compound heterozygous novel variants identified by trio-based exome sequencing. She carries the paternally inherited delins variant c.158_161delinsTCAT, p.(Arg53_Asn54delinsLeuIle) and the maternally inherited frameshift variant c.567del, p.(Thr190ProfsTer9) in FITM2 gene. The patient exhibits the main features of the disease, including deafness, intellectual disability, regression of motor skills and poor overall growth. Additionally, she presents with spastic paraplegia which supports recent phenotypic expansion. We describe for the first time, novel brain magnetic resonance imaging signal alterations, not previously associated with this disorder. These neuroimaging findings may provide new insights into the neurological manifestations of Siddiqi syndrome. This case expands the phenotypic and molecular spectrum of FITM2 associated disease and emphasizes the adult-features of this syndrome. [Image: see text]

#5

KMT2B-related disorders in Austria: clinical features and long-term outcome after deep brain stimulation.

Frontiers in neurology2026

Since its initial description in 2016, DYT-KMT2B has emerged as one of the most common genetic causes of early-onset dystonia. Subsequent reports have expanded its phenotypic spectrum, frequently including neurodevelopmental features. Deep brain stimulation of the globus pallidus internus (GPi DBS) has become a therapeutic mainstay; however, most published data are based on single cases or short-term observations, and long-term outcomes remain poorly characterized. We report the clinical course and response to GPi DBS in nine patients with KMT2B variants prospectively followed at two Austrian national reference centers for rare movement disorders. Long-term follow-up data (range: 5-20 years) were available for six patients. Clinical features and treatment outcomes were compared with previously published cohorts. Non-motor features such as developmental delay, intellectual disability, and epilepsy were more frequent in our cohort than in earlier reports. All patients developed generalized dystonia and bulbar involvement over time, emphasizing the progressive nature of the disease. Despite secondary symptom worsening during long-term follow-up, GPi DBS preserved ambulation in three patients and enabled sustained recovery of walking ability in two, maintaining functional independence. Surgical correction of foot deformities further supported mobility. Notably, KMT2B variants were identified upon genetic re-evaluation in two patients previously diagnosed with dyskinetic cerebral palsy. Our long-term data underscore the progressive but heterogeneous course of DYT-KMT2B. GPi DBS offers durable clinical benefits, particularly when initiated before loss of ambulation. Early surgical intervention and multidisciplinary management are essential to optimize long-term outcomes.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1 artigos no totalmostrando 198

2026

Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity.

Journal of inherited metabolic disease
2026

Expanding the Phenotypic Spectrum of the Recurrent De Novo FBXO31 p.Asp334Asn Variant: Evidence for a Novel Neurodevelopmental Disorder (Kruer Syndrome).

Clinical genetics
2026

The Movement Disorder Spectrum of ATP1A3-Related Disorders: Cross-Sectional Analysis and Video Archive of 88 Patients.

Movement disorders : official journal of the Movement Disorder Society
2026

Expanding the Genotypic Spectrum of SLC18A2 Mutation-Related Disorder-A Novel Mutation and Review of Literature.

Journal of child neurology
2026

Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine.

Case reports in neurological medicine
2026

Clinical, Radiological, and Genetic Profile of Patients with FA2H-Associated Neurodegeneration: Eight Cases from India and a Review of the Literature.

Tremor and other hyperkinetic movements (New York, N.Y.)
2026

Genetic and therapeutic insights in musician's dystonia: a single-centre case series and narrative review.

Acta neurologica Belgica
2026

Adult-Onset PLA2G6-Associated Parkinsonism With Claval Hypertrophy: A Rare Radiological-Genetic Association.

Cureus
2026

Neuroradiological Phenotype Expansion of the Siddiqi Syndrome: A Case Report.

Cellular and molecular neurobiology
2026

KMT2B-related disorders in Austria: clinical features and long-term outcome after deep brain stimulation.

Frontiers in neurology
2026

From genotype to outcome: Zygosity-specific insights in 63 cases of CLPB-related mitochondrial disease.

Molecular genetics and metabolism
2026

Nocturnal Ballistic Bouts in ADCY5-Related Movement Disorder.

Cureus
2026

Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.

Frontiers in aging neuroscience
2026

Cardiofaciocutaneous Syndrome Type 4 due to a MAP2K2 Variant: Expanding the Phenotypic Spectrum With Feeding Dysfunction and Neurodevelopmental Involvement.

Clinical case reports
2026

Familial Dystonia Due to Homozygous TPI1 c.718G>A (p.Glu240Lys): A Three-Sibling Case Series Including Two Treated with Deep Brain Stimulation of the Globus Pallidus Internus.

Annals of Indian Academy of Neurology
2026

Loss-of-function variants in the CAPN1 activator CD99L2 cause X-linked spastic ataxia.

Nature communications
2026

DYT-AOPEP: A case series from India expanding the clinical and genetic spectrum.

Parkinsonism & related disorders
2026

[How do I explore… a dystonia in 2026].

Revue medicale de Liege
2026

Childhood-onset ataxia with dystonia: expanding the spectrum of VWA3B-related disorders.

Journal of human genetics
2026

Early Diagnosis and Targeted Therapy in SLC39A8-Congenital Disorder of Glycosylation: A Case Report From Bulgaria.

Cureus
2026

A Case of Familial Paroxysmal Non-kinesigenic Dyskinesia in Mainland China: A Clinical and Genetic Investigation.

Cureus
2025

Novel NPRL3 variant associated with sleep-related hypermotor epilepsy: a case report and educational review.

Frontiers in neuroscience
2026

Expanding the Genetic Landscape of ATXN2 Variants: Insights From a Biallelic Trinucleotide Repeat Expansion in an Acadian Family.

Neurology. Genetics
2026

Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort.

Annals of neurology
2025

Infantile Epsilon-Sarcoglycan (SGCE) Myoclonus-Dystonia: Diagnostic Pitfalls and Poor Response to Pharmacologic Treatment.

Cureus
2026

Selective Sparing of the Medial Medullary Lamina on MRI: Diagnostic Clue to a Rare Genetic Dystonia.

Indian journal of pediatrics
2026

A rare GCH1 p.Arg170Gly variant shows impaired enzymatic activity and co-occurs with a novel NEXMIF p.Asp155GlnfsTer2 leading to a complex neurological phenotype: functional studies and clinical aspects.

Molecular genetics and metabolism
2026

Bilateral Globus Pallidus Deep Brain Stimulation Improves Motor Function in ADCY5-Related Disorder.

Movement disorders : official journal of the Movement Disorder Society
2025

Case Report: Myoclonic and tremulous movements associated with COQ8A-related coenzyme Q10 deficiency type 4.

Frontiers in genetics
2026

Therapeutic suppression of Tubb4a rescues H-ABC leukodystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Long-term benefit of GPi-DBS in YY1-related dystonia: a case report.

Acta neurologica Belgica
2026

Clinical and Genetic Characteristics of Paroxysmal Kinesigenic Dyskinesia: A Single-Center Study and Literature Review.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Sex-related differences in the short and long-term outcome of internal pallidus stimulation for dystonia.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Efficacy of Deep Brain Stimulation for the Treatment of Monogenic Dystonia Symptoms: A Systematic Review.

European journal of neurology
2026

FTH1-Related Neuroferritinopathy: A Rare Form of Neurodegeneration with Brain Iron Accumulation Mimicking Pontocerebellar Hypoplasia.

Movement disorders clinical practice
2026

Phenotypic Spectrum of Type 2-3 Gaucher Disease: A Case Study in the Balkan Genotype.

The American journal of case reports
2026

Genotypic and radiological expansion of CONDSIAS.

BMJ case reports
2026

Spinocerebellar ataxia type 40 presenting with isolated cervical dystonia: expanding the phenotypic spectrum.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Dystonia-deafness syndrome 1 caused by ACTB p.(Arg183Trp) de novo variant: one novel case extending the phenotypic spectrum.

Neurogenetics
2026

DBSMatchMaker: Global Uptake and Insights from the First Year of a Collaborative Deep Brain Stimulation Platform.

Movement disorders : official journal of the Movement Disorder Society
2025

Longitudinal Syringomyelia, Cervical Dystonia, and Action Tremor in Trichorhinophalangeal Syndrome Type I - A Case Report.

Tremor and other hyperkinetic movements (New York, N.Y.)
2025

CAPOS and Beyond: ATP1A3 Variants in Pediatric Movement Disorders - Case Reports.

Molecular syndromology
2025

Hypoglycemic Encephalopathy With Multisystem Organ Dysfunction in an Infant With MEGD(H)EL Syndrome.

Cureus
2026

DNAJC12 Disease: Clinical Spectrum and Long-Term Outcomes.

Neurology. Genetics
2025

ANO3-related tremulous dystonia: case report.

Acta neurologica Belgica
2025

Navigating the Uncommon: "Juvenile-Onset Huntington Disease".

Journal of child neurology
2025

Neurodevelopmental Disorder with Psychomotor Delay, Hearing Loss, and Spasticity Caused by Compound Heterozygous SPATA5L1 Variants-Expanding Phenotype.

Journal of clinical medicine
2025

A Novel VPS13A Deletion in VPS13A Disease (Chorea-Acanthocytosis): A Case Report with Brief Literature Summary.

International journal of molecular sciences
2026

Expanding the genotypic and phenotypic spectrum of DYT-TSPOAP1: First report from India.

Parkinsonism & related disorders
2025

Concurrent surgical management of pineoblastoma and Chiari type 1.5 malformation: a case report.

BMC surgery
2025

ACTB-associated dystonia-deafness syndrome with good response to DBS GPi revisited.

Clinical parkinsonism & related disorders
2025

From SGCE gene to symptoms: decoding myoclonus-dystonia.

Acta neurologica Belgica
2025

L-DOPA in diurnal fluctuating dystonia: two different clinical presentations, one treatment.

Neurogenetics
2025

Paroxysmal Kinesigenic Dyskinesia Caused by 16p11.2 Microdeletion: A Case Report.

Case reports in neurology
2025

Neurodegeneration With Brain Iron Accumulation and Ferroptosis Disorders in Children and Adults: An Imaging Review.

Journal of neuroimaging : official journal of the American Society of Neuroimaging
2025

Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonism.

medRxiv : the preprint server for health sciences
2025

Clinical spectrum and outcomes of anti-metabotropic glutamate receptor 5 encephalitis in Chinese patients: a case report and literature review.

Frontiers in immunology
2025

Iron Dysregulation in Neurodegeneration with Brain Iron Accumulation (NBIA): Links between Mutations Occurring in BPAN, PKAN, MPAN and PLAN Types and Iron Metabolism.

Molecular neurobiology
2025

[Type 28 spinocerebellar ataxia].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Biallelic variants in TNR cause neurodevelopmental disorders with variable expressivity.

Journal of human genetics
2025

Postinfectious Manifestation of Wilson's Disease in COVID-19 Presenting as Writer's Cramp: A Case Report.

Acta neurologica Taiwanica
2025

Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.

Journal of inherited metabolic disease
2026

Expanding the Genetic and Phenotypic Spectrum of DYT-VPS16: The Importance of Splice-Site Variants.

Movement disorders : official journal of the Movement Disorder Society
2025

Homozygous Pathogenic MYH3 Variants Associated With Arthrogryposis and Lingual Dystonia.

Tremor and other hyperkinetic movements (New York, N.Y.)
2025

SCN3A-related neurodevelopmental disorder: Clinical case reports and biophysical characterization.

Channels (Austin, Tex.)
2025

Severe upper airway dysfunction in GNAO1-related disorders.

Italian journal of pediatrics
2026

Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency.

Movement disorders : official journal of the Movement Disorder Society
2026

Genetic complexity in pediatric onset epilepsy-movement disorder syndromes: Insights from a cohort of 97 subjects.

Epilepsia
2025

Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases.

Movement disorders clinical practice
2025

FITM2-Related Siddiqi Syndrome in Two Iranian Siblings.

Clinical case reports
2026

Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society
2025

Biallelic NDUFA9 variants cause a progressive neurodevelopmental disorder with prominent dystonia and mitochondrial complex I deficiency.

Brain communications
2025

RRP12 Variants Are Associated With Autosomal Recessive Brain Calcifications.

Movement disorders : official journal of the Movement Disorder Society
2025

Ketogenic diet for alternating hemiplegia of childhood: Case report and literature review.

Medicine
2025

Mutations in the Key Autophagy Tethering Factor EPG5 Link Neurodevelopmental and Neurodegenerative Disorders Including Early-Onset Parkinsonism.

Annals of neurology
2026

Integrating Long-Read Nanopore Sequencing for Precision Resolution of Genomic Variants in Dystonia.

Movement disorders : official journal of the Movement Disorder Society
2026

Managing Dystonia in Partington Syndrome.

Movement disorders clinical practice
2025

Association of alcohol responsiveness and non-motor symptoms in isolated adult-onset dystonia.

Journal of neurology
2025

A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features.

Molecular neurodegeneration
2025

MCT8 Deficiency in Infancy: Opportunities for Early Diagnosis and Screening.

International journal of neonatal screening
2026

VPS16-Related Dystonia: Expanding the Clinical Spectrum and Therapeutic Insights.

Movement disorders clinical practice
2025

Functional Characterization and Pathogenicity Classification of PRRT2 Splice Variants in PRRT2-Related Disorders.

Annals of clinical and translational neurology
2025

Paroxysmal Dyskinesias in Paediatric Age: A Systematic Review.

Journal of clinical medicine
2025

Isolated Non-Progressive Hemidystonia in a Patient Homozygous for H63D Variant of Hereditary Hemochromatosis: A Case Report and Systematic Literature Review of Movement Disorders in Hereditary Hemochromatosis.

Diagnostics (Basel, Switzerland)
2025

Genetic and clinical profile of a Brazilian cohort of dopa-responsive dystonia.

Journal of the neurological sciences
2025

Preliminary observations of glucose metabolism dysregulation in pediatric Huntington's disease.

Frontiers in neurology
2025

Case Report of Pediatric HPCA-Associated Dystonia: Analysis of Ca2+ and K+ Channel Dynamics and Experience With Pallidal Deep Brain Stimulation.

Pediatric neurology
2025

Long-Term Efficacy of Bilateral Globus Pallidus Internus Deep Brain Stimulation in Myoclonus-Dystonia Associated with KCNN2 Gene Mutation: A Case Study.

International journal of molecular sciences
2025

A Homozygous c.74A>G Variant in PRKRA Causes DYT-PRKRA: Extensive Familial Segregation and a Variant of Uncertain Significance (VUS) Reclassification.

Movement disorders : official journal of the Movement Disorder Society
2025

Deep Brain Stimulation in Children and Adolescents with ε-Sarcoglycan Myoclonus Dystonia Causes a Sustained Improvement in Motor Functionality and Quality of Life.

Movement disorders : official journal of the Movement Disorder Society
2025

Biallelic TSEN2 variants causing pontocerebellar hypoplasia type 2.

Journal of human genetics
2025

Unravelling neurodegeneration with cerebral calcifications: Krabbe disease masquerading as Aicardi-Goutieres syndrome.

BMJ case reports
2025

Treatable and preventable causes of inborn errors of metabolism: Cohort of neurotransmitter disorders in children from India.

Brain & development
2026

Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy.

Brain : a journal of neurology
2025

The mitochondrial trans-2-enoyl-CoA reductase is necessary for mitochondrial homeostasis in C. elegans.

Genetics
2025

Identification of three novel GNAO1 variants in a Chinese cohort with GNAO1 encephalopathy: expanding the clinical and genetic spectrum.

Orphanet journal of rare diseases
2025

Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.

Nature medicine
2025

Biomarker Validation in NPC1: Foundations for Clinical Trials and Regulatory Alignment.

Journal of inherited metabolic disease
2026

Molecular and clinical spectrum of epilepsy-dyskinesia syndromes: a cross-sectional study of 609 patients.

Brain : a journal of neurology
2025

Rare PANK2 variants and pantothenate-kinase-associated neurodegeneration in the Dominican Republic.

Brain communications
2025

Extraocular features of Leber hereditary optic neuropathy: A scoping review.

Journal of biological methods
2025

Case report of paroxysmal dystonia in a child with KBG syndrome: Expansion of the phenotype and utility of whole exome sequencing.

Medicine
2025

Atypical neuroaxonal dystrophy in childhood related to PLA2G6: a French cohort.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Rapid-onset dystonia-parkinsonism: First African case of ATP1A3 mutation.

Parkinsonism & related disorders
2025

FBXO7 Pathogenic Variants in Early-Onset Parkinsonism: Insights from a Neuroimaging Perspective and Review of the Literature.

Movement disorders clinical practice
2025

Novel Biallelic SQSTM1 Mutation Causing a Subacute-Onset Complex Movement Disorder with Oculomotor Abnormalities.

Movement disorders clinical practice
2025

Pediatric Genetic Dystonias: Current Diagnostic Approaches and Treatment Options.

Life (Basel, Switzerland)
2025

Gene editing for Spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene.

Gene therapy
2025

Deep Brain Stimulation in Leigh-Like Syndrome Due to DNM1 Pathogenic Variant.

Tremor and other hyperkinetic movements (New York, N.Y.)
2025

SGCE Myoclonus Dystonia: A Case Report.

Ethiopian journal of health sciences
2026

Neurological diagnoses in children potentially fulfilling the criteria for developmental coordination disorder.

Developmental medicine and child neurology
2025

Hearing rehabilitation in SERAC1 related MEGD(H)EL syndrome - implications from a multi-center retrospective cohort study.

Molecular genetics and metabolism
2025

Rare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson's Disease.

medRxiv : the preprint server for health sciences
2025

Rare Movement Disorders-An Approach for Clinicians.

International journal of molecular sciences
2025

Assessment of neurological symptoms and associated factors in patients with Wilson's disease in Southwest China.

Orphanet journal of rare diseases
2025

Genetic and Clinical Features of SLC2A1-Related Paroxysmal Exercise-Induced Dyskinesia.

Pediatric neurology
2025

A novel TIMM8A mutation in Mohr-Tranebjaerg syndrome without hearing loss and with basal ganglia iron deposition.

Orphanet journal of rare diseases
2025

The Spectrum of Neurologic Phenotypes Associated With NUS1 Pathogenic Variants: A Comprehensive Case Series.

Annals of neurology
2025

Variant Ataxia-Telangiectasia Presenting as Tremor-Dystonia Syndrome in a Bulgarian Religious Minority.

Genes
2025

Clinico-genetic profile of case series of six Tamilian chorea-acanthocytosis families with VPS13A mutations from South India.

Parkinsonism & related disorders
2025

Dynamic electro-clinical features in Guanidinoacetate N-methyltransferase deficiency: A familial case series.

Epilepsia open
2025

Deep Brain Stimulation for VPS16-Related Dystonia: A Multicenter Study.

Annals of neurology
2025

Genetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large-Scale Exome Sequencing.

Annals of clinical and translational neurology
2026

Identifying the Fourth Patient With Spastic Paraplegia 90, Extending the Phenotype Spectrum.

Clinical genetics
2025

CLCN2-related leukoencephalopathy with ataxia (LKPAT) and dystonia in two unrelated Indian patients.

Parkinsonism & related disorders
2025

ADCY5-Mosaic Variants: A Diagnosis Not to Be Missed.

Movement disorders clinical practice
2025

Phenotypic Diversity in Stress-induced Childhood-Onset Neurodegeneration with Variable Ataxia and Seizures: Novel Associations with Parkinsonism, Icthyosis and Cataract.

Cerebellum (London, England)
2025

High Genetic Diagnostic Yield for Patients with Rare Movement Disorders at a Single-Center Neurogenetics Clinic.

Movement disorders clinical practice
2025

The organizational dimension in rare and complex diseases care management: an application of RarERN Path© methodology in ataxias, dystonia and phenylketonuria.

BMC health services research
2025

Neurodegeneration, Intracranial Calcifications, Microcephaly and Drug-Resistant Epilepsy Caused by a Novel Homozygous Missense Variant in the NRROS Gene: A Case Report.

International medical case reports journal
2026

EAST syndrome: when the nephrologist calls the neurologist.

Practical neurology
2025

Parkinsonism and Dystonia Are Prevalent and Concomitant Movement Disorders in a Cohort of Patients with Rett Syndrome.

Movement disorders clinical practice
2025

Dopa-responsive dystonia and phenotypes associated with TH gene variants: a systematic review and Mexican case series.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Pontocerebellar Hypoplasia Type 1 and Associated Neuronopathies.

Genes
2025

Novel CYFIP2 Frameshift Variant Linked to Dyskinetic Crises: Functional Studies Show Impaired Cell Motility.

Clinical genetics
2025

Neuromelanosis masquerading as tubercular bacterial meningitis.

BMJ case reports
2025

Status Dystonicus in Children: Is it more Common than we Realize?

Movement disorders clinical practice
2025

Alternating hemiplegia of childhood associated mutations in Atp1a3 reveal diverse neurological alterations in mice.

Neurobiology of disease
2025

Development and Preliminary Validation of a Parkinsonism-Dystonia Scale for Infants and Young Children.

Movement disorders : official journal of the Movement Disorder Society
2025

Genotype-Phenotype Relations for the Dystonia-Parkinsonism Genes GLB1, SLC6A3, SLC30A10, SLC39A14, and PLA2G6: MDSGene Systematic Review.

International journal of molecular sciences
2025

Aberrant outputs of glutamatergic neurons in deep cerebellar nuclei mediate dystonic movements.

Science advances
2025

KIF5A variant in familial dystonia: A clinicogenetic study of a large Roma kindred.

Parkinsonism & related disorders
2025

Novel SPR mutation in first Chinese patient with sepiapterin reductase deficiency: urinary biomarker validation in oldest treated case.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

De Novo Variants in Siblings: A Rare Occurrence of Two Unrelated Pathogenic Mutations.

Movement disorders clinical practice
2025

Pearls & Oy-sters: ADCY5-Related Dyskinesia: From a Longstanding Misdiagnosis of Drug-Resistant Epilepsy.

Neurology
2025

A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches.

Journal of medicine and life
2025

Glutaric aciduria type-1 in a teenager with nutritional vitamin B12 deficiency: coexistence of two treatable conditions.

BMJ case reports
2025

The Rare Syndrome Aicardi-Goutières 4: A Case Report and Literature Review.

Developmental neurobiology
2025

Biallelic Variants in AFG3L2 Causing Spastic Ataxia Type 5 (SPAX5): Report of Two Pediatric Cases from Bogotá, Colombia.

Movement disorders clinical practice
2025

Unusual Phenotypic Variability in Paroxysmal Dystonia Associated with Rare ATP1A3 Mutation: A Case Report and Review.

Journal of child neurology
2025

Efficacy of deep brain stimulation in treating monogenic dystonia symptoms: protocol for a systematic review.

BMJ open
2025

Expanding the Clinical and Genetic Spectrum of Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency: Insights From Two Unrelated Chinese Families.

Molecular genetics & genomic medicine
2025

Systemic Primary Carnitine Deficiency Presenting With Substantia Nigra and Basal Ganglia Injury: A Case Report.

JIMD reports
2025

Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature.

Neuro-ophthalmology (Aeolus Press)
2025

The wide phenotypic spectrum of thiamine metabolism dysfunction syndrome 5 and its treatment.

Orphanet journal of rare diseases
2025

Paroxysmal Kinesigenic Dyskinesia in Two Siblings With Novel Heterozygous TMEM151A Frameshift Variant: The First Case Report in Japan.

American journal of medical genetics. Part A
2025

Delayed Diagnosis of Aicardi-Goutières Syndrome in a 10-Year-Old Female Child With TREX1 Mutation: A Case Report.

Cureus
2025

Dopa responsive dystonia due to a GCH1 gene variant mimicking hereditary spastic paraparesis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Corrigendum to "Variable expressivity of KMT2B variants at codon 2565 in patients with dystonia and developmental disorders" [Parkinson. Relat. Disord. (2025) 133 107319].

Parkinsonism & related disorders
2025

Insights on the Shared Genetic Landscape of Neurodevelopmental and Movement Disorders.

Current neurology and neuroscience reports
2025

Case report: Whole exome sequencing identifies a novel variant in the HPRT1 gene in a male with developmental delay.

Frontiers in genetics
2025

TOR1AIP2 as a candidate gene for dystonia-hemichorea/hemiballism.

Parkinsonism & related disorders
2025

Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment.

Movement disorders : official journal of the Movement Disorder Society
2025

Approach to Myoclonus Dystonia Syndrome: A European Reference Network Survey.

Movement disorders clinical practice
2025

Treatment Efficacy of Theophylline in ADCY5-Related Dyskinesia: A Retrospective Case Series Study.

Movement disorders : official journal of the Movement Disorder Society
2024

Hypermagnesemia with Dystonia Type 2: Case Report of a New SLC30A10 Variant.

Journal of pharmacy & bioallied sciences
2025

Genotype-Phenotype Landscape of NALCN and UNC80-Related Disorders.

Neurology
2025

KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation.

ArXiv
2025

Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case series.

The Lancet. Neurology
2025

A case series of nine patients with cerebrotendinous xanthomatosis from India and a systematized review of Indian literature.

Parkinsonism & related disorders
2025

AAV-Mediated Gene Transfer of WDR45 Corrects Neurological Deficits in the Mouse Model of Beta-Propeller Protein-Associated Neurodegeneration.

Human gene therapy
2025

Commentary on "Atypical ADCY5-related movement disorders: Highlighting adolescent/adult-onset cervical dystonia".

Parkinsonism & related disorders
2025

Complex Multifocal Dystonia, Intellectual Disability, and Stereotypies Due to a Novel DYRK1A Variant.

Movement disorders clinical practice
2025

Biotin Induces Inactive Chromosome X Reactivation and Corrects Physiopathological Alterations in Beta-Propeller-Protein-Associated Neurodegeneration.

International journal of molecular sciences
2025

Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia.

Brain : a journal of neurology
2025

Movement Disorders in Hereditary Cerebellar Ataxia.

Movement disorders clinical practice
2025

Variable expressivity of KMT2B variants at codon 2565 in patients with dystonia and developmental disorders.

Parkinsonism & related disorders
2025

PLA2G6-associated Neurodegeneration: A Rare Case Report of Dystonia-Parkinsonism Phenotype with a Novel Genotypic Variant.

The Journal of the Association of Physicians of India
2025

Clinical spectrum, treatment and outcomes of the m.10197G>A mutation in MT-ND3: a case report, systematic review and meta-analysis.

Orphanet journal of rare diseases
2025

Generation of an induced pluripotent stem cell line (UCLi026-A) from a patient with ADCY5-related disease carrying the heterozygous variant c.1253G > A; (p. Arg418Gln).

Stem cell research
2024

Case Report: The first Korean familial case of BCAP31-related deafness, dystonia, and cerebral hypomyelination.

Frontiers in pediatrics
2025

Atypical ADCY5-related movement disorders: Highlighting adolescent/adult-onset cervical dystonia.

Parkinsonism & related disorders
2025

Deletion of the THAP1 Gene Is Responsible for Typical DYT-THAP1.

Movement disorders clinical practice
2025

A Novel Large Duplication on the X Chromosome as a Cause of Familial Generalized Dystonia: A Case Report.

International journal of molecular sciences
2025

Functional movement disorders in dopa-responsive dystonia.

Parkinsonism & related disorders
2025

Neuronal ceroid lipofuscinosis 11 (CLN11) presenting with early-onset cone-rod dystrophy and learning difficulties.

Neurogenetics
2025

Genomic characterization of Huntington's disease genetic modifiers informs drug target tractability.

Brain communications
2025

Dystonia caused by ANO3 variants is due to attenuated Ca2+ influx by ORAI1.

BMC medicine
2024

Studying Rare Movement Disorders: From Whole-Exome Sequencing to New Diagnostic and Therapeutic Approaches in a Modern Genetic Clinic.

Biomedicines
2025

Baricitinib Treatment in RNU7-1-Associated Aicardi-Goutières Syndrome in a South African Child: A Case Report.

American journal of medical genetics. Part A
2024

[A case of rare hereditary Siddiqi syndrome with novel neuropsychiatric signs].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Challenges in Describing Tremor and Dystonia.

Neurology
2024

ATP1A3-Associated Paroxysmal Dystonia.

Tremor and other hyperkinetic movements (New York, N.Y.)
2025

Natural history of SGCE-associated myoclonus dystonia in children and adolescents.

Developmental medicine and child neurology
2024

Rare Spinocerebellar Ataxia Types in Canada: A Case Series and Review of the Literature.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

Novel compound heterozygous P4HTM variants in a girl with developmental and epileptic encephalopathy: First case report of P4HTM variant-associated epileptic encephalopathy.

Seizure
2024

A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study.

Orphanet journal of rare diseases
2024

Novel mouse model of alternating hemiplegia of childhood exhibits prominent motor and seizure phenotypes.

Neurobiology of disease

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distonia genética rara.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distonia genética rara

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity.
    Journal of inherited metabolic disease· 2026· PMID 41872043mais citado
  2. Expanding the Phenotypic Spectrum of the Recurrent De Novo FBXO31 p.Asp334Asn Variant: Evidence for a Novel Neurodevelopmental Disorder (Kruer Syndrome).
    Clinical genetics· 2026· PMID 41858232mais citado
  3. Expanding the Genotypic Spectrum of SLC18A2 Mutation-Related Disorder-A Novel Mutation and Review of Literature.
    Journal of child neurology· 2026· PMID 41804711mais citado
  4. Neuroradiological Phenotype Expansion of the Siddiqi Syndrome: A Case Report.
    Cellular and molecular neurobiology· 2026· PMID 41758270mais citado
  5. KMT2B-related disorders in Austria: clinical features and long-term outcome after deep brain stimulation.
    Frontiers in neurology· 2026· PMID 41738007mais citado
  6. Pediatric Dental Management of a Patient With Infantile Osteopetrosis in Remission: A Clinical Case Report.
    Case Rep Dent· 2026· PMID 41994596recente
  7. Ophthalmic manifestations and management of Traboulsi syndrome in three children of a Saudi family.
    Saudi J Ophthalmol· 2026· PMID 41994245recente
  8. Severe polyarterial involvement in a 16-year-old with homozygous familial hypercholesterolaemia: a case report.
    Eur Heart J Case Rep· 2026· PMID 41993942recente
  9. WNT5a-Mediated Aberrant Actin Filament Dynamics Drive Cardiac Pathogenic Phenotypes in LMNA-Related Emery-Dreifuss Muscular Dystrophy.
    Circulation· 2026· PMID 41993022recente
  10. Case Report: Neonatal PURA syndrome caused by a novel c.463C>G (p.Tyr155Ter) mutation.
    Front Pediatr· 2026· PMID 41988154recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:391799(Orphanet)
  2. MONDO:0044807(MONDO)
  3. Distonia e Espasticidade(PCDT · Ministério da Saúde)
  4. GARD:21630(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q55787960(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distonia genética rara
Compêndio · Raras BR

Distonia genética rara

ORPHA:391799 · MONDO:0044807
🇧🇷 Brasil SUS
Geral
Medicamentos
4 registrados
MedGen
UMLS
C0752207
Repurposing
1 candidato
procyclidineacetylcholine receptor antagonist
EuropePMC
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades